Literature DB >> 27856425

PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors.

Marcela A Haro1, Chad A Littrell1, Zhaojun Yin2, Xuefei Huang2, Karen M Haas3.   

Abstract

Tn is a carbohydrate antigen uniquely exposed on tumor mucins and, thus, an ideal target for immunotherapy. However, it has been difficult to elicit protective antibody responses against Tn antigen and other tumor-associated carbohydrate antigens. Our study demonstrates this can be attributed to PD-1 immuno-inhibition. Our data show a major role for PD-1 in suppressing mucin- and Tn-specific B-cell activation, expansion, and antibody production important for protection against Tn-bearing tumor cells. These Tn/mucin-specific B cells belong to the innate-like B-1b cell subset typically responsible for T cell-independent antibody responses. Interestingly, PD-1-mediated regulation is B cell-intrinsic and CD4+ cells play a key role in supporting Tn/mucin-specific B-cell antibody production in the context of PD-1 deficiency. Mucin-reactive antibodies produced in the absence of PD-1 inhibition largely belong to the IgM subclass and elicit potent antitumor effects via a complement-dependent mechanism. The identification of this role for PD-1 in regulating B cell-dependent antitumor immunity to Tn antigen highlights an opportunity to develop new therapeutic strategies targeting tumor-associated carbohydrate antigens. Cancer Immunol Res; 4(12); 1027-37. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27856425      PMCID: PMC5373664          DOI: 10.1158/2326-6066.CIR-16-0184

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  50 in total

1.  Chemical structure of epiglycanin, the major glycoprotein of the TA3-Ha ascites cell. The carbohydrate chains.

Authors:  D H Van den Eijnden; N A Evans; J F Codington; V Reinhold; C Silber; R W Jeanloz
Journal:  J Biol Chem       Date:  1979-12-10       Impact factor: 5.157

Review 2.  Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential.

Authors:  Morganna Freeman-Keller; Jeffrey S Weber
Journal:  Ther Adv Med Oncol       Date:  2015-01       Impact factor: 8.168

Review 3.  CD20+ B cells: the other tumor-infiltrating lymphocytes.

Authors:  Brad H Nelson
Journal:  J Immunol       Date:  2010-11-01       Impact factor: 5.422

Review 4.  Vaccination with Theratope (STn-KLH) as treatment for breast cancer.

Authors:  Leona A Holmberg; Brenda M Sandmaier
Journal:  Expert Rev Vaccines       Date:  2004-12       Impact factor: 5.217

5.  Carbohydrate structures of bovine submaxillary mucin.

Authors:  T Tsuji; T Osawa
Journal:  Carbohydr Res       Date:  1986-08-15       Impact factor: 2.104

6.  Primate B-1 cells generate antigen-specific B cell responses to T cell-independent type 2 antigens.

Authors:  Rama D Yammani; Karen M Haas
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

7.  Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine.

Authors:  Yu-Fei He; Gui-Mei Zhang; Xiao-Hong Wang; Hui Zhang; Ye Yuan; Dong Li; Zuo-Hua Feng
Journal:  J Immunol       Date:  2004-10-15       Impact factor: 5.422

8.  Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA).

Authors:  P Y Fung; B M Longenecker
Journal:  Cancer Res       Date:  1991-02-15       Impact factor: 12.701

Review 9.  Emerging principles for the therapeutic exploitation of glycosylation.

Authors:  Martin Dalziel; Max Crispin; Christopher N Scanlan; Nicole Zitzmann; Raymond A Dwek
Journal:  Science       Date:  2014-01-03       Impact factor: 47.728

10.  Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages.

Authors:  P Allavena; M Chieppa; G Bianchi; G Solinas; M Fabbri; G Laskarin; A Mantovani
Journal:  Clin Dev Immunol       Date:  2011-02-09
View more
  12 in total

1.  Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.

Authors:  Xuanjun Wu; Zhaojun Yin; Craig McKay; Christian Pett; Jin Yu; Manuel Schorlemer; Trevor Gohl; Suttipun Sungsuwan; Sherif Ramadan; Claire Baniel; Anthony Allmon; Rupali Das; Ulrika Westerlind; M G Finn; Xuefei Huang
Journal:  J Am Chem Soc       Date:  2018-11-19       Impact factor: 15.419

2.  B Cell Subsets Differentially Contribute to the T Cell-Independent Memory Pool.

Authors:  Christina A Daly; M Ariel Spurrier; Jamie E Jennings-Gee; Karen M Haas
Journal:  J Immunol       Date:  2020-09-25       Impact factor: 5.422

3.  A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.

Authors:  Timothy S Pardee; Rebecca G Anderson; Kristin M Pladna; Scott Isom; Lais P Ghiraldeli; Lance D Miller; Jeff W Chou; Guangxu Jin; Wei Zhang; Leslie R Ellis; Dmitriy Berenzon; Dianna S Howard; David D Hurd; Megan Manuel; Sarah Dralle; Susan Lyerly; Bayard L Powell
Journal:  Clin Cancer Res       Date:  2018-02-06       Impact factor: 12.531

4.  PD-L1/B7-H1 Inhibits Viral Clearance by Macrophages in HSV-1-Infected Corneas.

Authors:  Sohyun Jeon; Alexander M Rowe; Kate L Carroll; Stephen A K Harvey; Robert L Hendricks
Journal:  J Immunol       Date:  2018-04-18       Impact factor: 5.422

5.  Evaluation of Virus-Like Particle-Based Tumor-Associated Carbohydrate Immunogen in a Mouse Tumor Model.

Authors:  Suttipun Sungsuwan; Xuanjun Wu; Xuefei Huang
Journal:  Methods Enzymol       Date:  2017-07-26       Impact factor: 1.600

6.  Type I IFN, Ly6C+ cells, and Phagocytes Support Suppression of Peritoneal Carcinomatosis Elicited by a TLR and CLR Agonist Combination.

Authors:  Allison M Dyevoich; Karen M Haas
Journal:  Mol Cancer Ther       Date:  2020-03-18       Impact factor: 6.261

7.  PD-L2 Regulates B-1 Cell Antibody Production against Phosphorylcholine through an IL-5-Dependent Mechanism.

Authors:  Jerome T McKay; Marcela A Haro; Christina A Daly; Rama D Yammani; Bing Pang; W Edward Swords; Karen M Haas
Journal:  J Immunol       Date:  2017-08-02       Impact factor: 5.422

8.  Activation of B-1 Cells Promotes Tumor Cell Killing in the Peritoneal Cavity.

Authors:  Marcela A Haro; Allison M Dyevoich; James P Phipps; Karen M Haas
Journal:  Cancer Res       Date:  2018-09-17       Impact factor: 12.701

Review 9.  The B-side of Cancer Immunity: The Underrated Tune.

Authors:  Anne Largeot; Giulia Pagano; Susanne Gonder; Etienne Moussay; Jerome Paggetti
Journal:  Cells       Date:  2019-05-13       Impact factor: 6.600

Review 10.  Specialized immune responses in the peritoneal cavity and omentum.

Authors:  Mingyong Liu; Aaron Silva-Sanchez; Troy D Randall; Selene Meza-Perez
Journal:  J Leukoc Biol       Date:  2020-09-02       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.